William Blair analyst Myles Minter has reiterated their bullish stance on IONS stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors that highlight the potential of Ionis Pharmaceuticals’ new product, Dawnzera. The recent FDA approval of Dawnzera for hereditary angioedema (HAE) treatment in both adults and children marks a significant milestone for the company. The product’s competitive edge is underscored by its patient-friendly auto-injector and flexible dosing schedule, which offers both once every four weeks and once every eight weeks options.
Minter’s rating is also influenced by the promising results from Ionis’s switch study, which demonstrated a substantial reduction in HAE attack rates among patients transitioning from existing treatments to Dawnzera. The study revealed that a significant majority of patients preferred Dawnzera over their previous treatments, indicating a strong market potential. These factors, combined with the unmet needs in the HAE treatment landscape, support the Buy recommendation for Ionis Pharmaceuticals.
According to TipRanks, Minter is a 5-star analyst with an average return of 15.9% and a 56.67% success rate. Minter covers the Healthcare sector, focusing on stocks such as Dianthus Therapeutics, Axsome Therapeutics, and Moderna.
In another report released today, Needham also maintained a Buy rating on the stock with a $55.00 price target.